Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108
Palisade Bio (Nasdaq: PALI) reported Q3 2024 financial results and key developments for PALI-2108, its lead program for treating moderate-to-severe Ulcerative Colitis (UC). The company has commenced enrollment and dosing in its Phase 1 clinical study. Notable achievements include presenting translational studies data at ACG's 2024 Annual Scientific Meeting, completing refined patient selection strategies with Strand Life Sciences, conducting a microbiome study confirming bacterial enzymes for local bioactivation, expanding intellectual property in Europe, and completing the first GMP batch of PALI-2108 drug substance.
Palisade Bio (Nasdaq: PALI) ha riportato i risultati finanziari del terzo trimestre 2024 e i principali sviluppi per PALI-2108, il suo programma principale per il trattamento della colite ulcerosa (UC) da moderata a severa. L'azienda ha avviato l'arruolamento e la somministrazione nel suo studio clinico di Fase 1. Tra i risultati significativi, si annoverano la presentazione di dati di studi traslazionali alla Riunione Scientifica Annuale dell'ACG 2024, il completamento di strategie di selezione dei pazienti con Strand Life Sciences, la conduzione di uno studio sul microbioma che conferma gli enzimi batterici per la bioattivazione locale, l'espansione della proprietà intellettuale in Europa e il completamento del primo lotto GMP della sostanza attiva del farmaco PALI-2108.
Palisade Bio (Nasdaq: PALI) informó sobre los resultados financieros del tercer trimestre de 2024 y los principales desarrollos de PALI-2108, su programa principal para tratar la colitis ulcerativa (UC) de moderada a severa. La compañía ha comenzado la inscripción y la dosificación en su estudio clínico de Fase 1. Entre los logros notables se encuentran la presentación de datos de estudios translacionales en la Reunión Científica Anual de la ACG 2024, la finalización de estrategias refinadas de selección de pacientes con Strand Life Sciences, la realización de un estudio del microbioma que confirma las enzimas bacterianas para la bioactivación local, la expansión de la propiedad intelectual en Europa y la finalización del primer lote GMP de la sustancia del medicamento PALI-2108.
팔리세이드 바이오 (Nasdaq: PALI)는 2024년 3분기 재무 결과와 중등도에서 중증의 궤양성 대장염(UC) 치료를 위한 주요 프로그램인 PALI-2108의 주요 발전 사항을 보고했습니다. 이 회사는 임상 1상 연구에 대한 등록 및 투약을 시작했습니다. 주목할 만한 성과로는 ACG 2024 연례 과학 회의에서의 전이 연구 데이터 발표, Strand Life Sciences와의 환자 선별 전략 개선 완료, 지역 생물 활성화를 위한 박테리아 효소 확인을 위한 마이크로바이옴 연구 수행, 유럽에서의 지적 재산권 확대, PALI-2108 의약품 물질의 첫 GMP 배치 완료가 있습니다.
Palisade Bio (Nasdaq: PALI) a annoncé les résultats financiers du troisième trimestre 2024 et les développements clés pour PALI-2108, son programme phare pour le traitement de la colite ulcéreuse (UC) modérée à sévère. La société a commencé l'inscription et le dosage dans son étude clinique de Phase 1. Parmi les réalisations notables figurent la présentation de données d'études translationnelles lors de la Réunion Scientifique Annuelle de l'ACG 2024, l'achèvement de stratégies de sélection de patients affinées avec Strand Life Sciences, la réalisation d'une étude sur le microbiome confirmant les enzymes bactériennes pour la bioactivation locale, l'expansion de la propriété intellectuelle en Europe et l'achèvement du premier lot GMP de la substance médicamenteuse PALI-2108.
Palisade Bio (Nasdaq: PALI) hat die finanziellen Ergebnisse des dritten Quartals 2024 und wichtige Entwicklungen für PALI-2108, sein Hauptprogramm zur Behandlung von moderater bis schwerer Colitis ulcerosa (UC), bekannt gegeben. Das Unternehmen hat die Einschreibung und Dosierung in seiner klinischen Phase-1-Studie aufgenommen. Zu den bemerkenswerten Erfolgen gehören die Präsentation von Daten aus translationalen Studien auf dem 2024 Annual Scientific Meeting der ACG, der Abschluss verfeinerter Patienten-Auswahlstrategien mit Strand Life Sciences, die Durchführung einer Mikrobiomstudie, die bakterielle Enzyme zur lokalen Bioaktivierung bestätigt, die Ausweitung des geistigen Eigentums in Europa und der Abschluss des ersten GMP-Batches des Arzneistoffs PALI-2108.
- Initiated Phase 1 clinical trial with patient enrollment and dosing for PALI-2108
- Received European patent notice for PALI-2108 and PALI-1908
- Completed first GMP batch of PALI-2108 drug substance
- Successfully demonstrated ex vivo bioactivation in clinical studies
- None.
Insights
Commenced enrollment and dosing in Phase 1 clinical study of PALI-2108 for the treatment of moderate-to-severe Ulcerative Colitis (UC)
Carlsbad, CA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today reported its financial results for the third quarter of 2024 and provided a business update.
Recent Highlights
- Commenced enrollment and dosed first subjects in its Phase 1 human clinical study of PALI-2108 for the treatment of moderate-to-severe UC;
- Presented data from two translational studies demonstrating the ex vivo bioactivation of PALI-2108 in stool samples and whole blood at the ACG’s 2024 Annual Scientific Meeting;
- Reported the completion of refined patient selection strategies based on PDE4-related biomarkers and disease characteristics to optimize clinical outcomes for patients with UC as part of its collaboration with Strand Life Sciences;
- Completed microbiome study confirming bacterial enzymes for local bioactivation of lead product candidate, PALI-2108, in development for Crohn’s disease and UC;
- Expanded intellectual property portfolio of PALI-2108 and PALI-1908 with a notice to grant patent from the European Patent Office; and
- Completed the first Good Manufacturing Practice (GMP) batch of drug substance PALI-2108, an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by UC.
“I am extremely proud of the clinical progress our team has made over this past quarter. The initiation of our Phase 1 clinical trial and patient enrollment and dosing are important milestones in our clinical program,” commented J.D. Finley, Chief Executive Officer of Palisade. “We continue to believe in the potential of PALI-2108 to provide a much-needed solution for UC patients still experiencing significant medical need.”
About PALI-2108
PALI-2108 is an orally administered, locally acting colon-specific PDE4 inhibitor prodrug in development for patients affected by UC. The Company continued to progress development of PALI-2108 and recently commenced a Phase 1 single-center, double-blind, placebo-controlled study focused on safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers, alongside an open-label study involving a patient cohort with UC. The comprehensive data gathered will support Palisade Bio's precision medicine strategy, aimed at identifying patient responders for future clinical studies.
Upcoming Target Milestones
- Phase 1 topline data expected in the first half of 2025; and
- Initiate Phase 1b/2a in the second half of 2025.
For more information about the Phase 1 clinical study, visit clinicaltrials.gov and reference identifier NCT06663605.
Summary of Financial Results for the Quarter Ended September 30, 2024
As of September 30, 2024, the Company had cash and cash equivalents of
Net loss was
Research and development expenses of approximately
General and administrative expenses decreased by
About Palisade Bio
Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com.
Forward Looking Statements
This communication contains “forward-looking” statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the extent of our cash runway; our ability to successfully develop our licensed technologies; the timing and outcome of our current and anticipated applications and studies related to our product candidates; estimates about the size and growth potential of the markets for our product candidates, and our ability to serve those markets, including any potential revenue generated; future regulatory, judicial, and legislative changes or developments in the United States (U.S.) and foreign countries and the impact of these changes; our ability to maintain the Nasdaq listing of our securities; our ability to build a commercial infrastructure in the U.S. and other markets; our ability to compete effectively in a competitive industry; our ability to identify and qualify manufacturers to provide API and manufacture drug product; our ability to enter into commercial supply agreements; the success of competing technologies that are or may become available; our ability to attract and retain key scientific or management personnel; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; our ability to obtain funding for our operations; our ability to attract collaborators and strategic partnerships; and the impact of any global event on our business, and operations, and supply. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon the Company’s current expectations. Forward-looking statements involve risks and uncertainties. The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the Company’s ability to advance its nonclinical and clinical programs, the uncertain and time-consuming regulatory approval process; and the Company’s ability to secure additional financing to fund future operations and development of its product candidates. Additional risks and uncertainties can be found in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 26, 2024, and any Quarterly Reports on Form 10-Q or other SEC filings that were filed thereafter. These forward-looking statements speak only as of the date hereof and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com
Palisade Bio, Inc.
Condensed Consolidated Balance Sheets (Unaudited)
(in thousands, except share and per share amounts)
September 30, | December 31, | |||||||
2024 | 2023 | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 8,040 | $ | 12,432 | ||||
Prepaid expenses and other current assets | 830 | 896 | ||||||
Total current assets | 8,870 | 13,328 | ||||||
Restricted cash | 26 | 26 | ||||||
Property and equipment, net | 3 | 10 | ||||||
Operating lease right-of-use asset | 113 | 198 | ||||||
Other noncurrent assets | 324 | 490 | ||||||
Total assets | $ | 9,336 | $ | 14,052 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 366 | $ | 698 | ||||
Accrued liabilities | 1,509 | 831 | ||||||
Accrued compensation and benefits | 449 | 778 | ||||||
Current portion of operating lease liability | 122 | 121 | ||||||
Insurance financing debt | 235 | 158 | ||||||
Total current liabilities | 2,681 | 2,586 | ||||||
Warrant liability | 2 | 2 | ||||||
Contingent consideration obligation | 45 | 61 | ||||||
Operating lease liability, net of current portion | — | 90 | ||||||
Total liabilities | 2,728 | 2,739 | ||||||
Commitments and contingencies | ||||||||
Stockholders' equity: | ||||||||
Series A Convertible Preferred Stock, 7,000,000 shares authorized; 200,000 issued and outstanding at September 30, 2024 and December 31, 2023 | 2 | 2 | ||||||
Common stock, 1,198,516 and 618,056 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively | 11 | 6 | ||||||
Additional paid-in capital | 139,195 | 132,811 | ||||||
Accumulated deficit | (132,600 | ) | (121,506 | ) | ||||
Total stockholders' equity | 6,608 | 11,313 | ||||||
Total liabilities and stockholders' equity | $ | 9,336 | $ | 14,052 |
Palisade Bio, Inc.
Condensed Consolidated Statements of Operations (Unaudited)
(in thousands, except share and per share amounts)
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||||||
License revenue | $ | — | $ | — | $ | — | $ | 250 | ||||||||
Operating expenses: | ||||||||||||||||
Research and development | 2,137 | 2,104 | 6,979 | 5,522 | ||||||||||||
General and administrative | 1,456 | 1,674 | 4,498 | 4,644 | ||||||||||||
Total operating expenses | 3,593 | 3,778 | 11,477 | 10,166 | ||||||||||||
Loss from operations | (3,593 | ) | (3,778 | ) | (11,477 | ) | (9,916 | ) | ||||||||
Other (expense) income: | ||||||||||||||||
Interest expense | (6 | ) | (8 | ) | (9 | ) | (11 | ) | ||||||||
Other income, net | 112 | 190 | 392 | 598 | ||||||||||||
Total other income, net | 106 | 182 | 383 | 587 | ||||||||||||
Net loss | $ | (3,487 | ) | $ | (3,596 | ) | $ | (11,094 | ) | $ | (9,329 | ) | ||||
Net loss available to common stockholders | $ | (3,487 | ) | $ | (3,612 | ) | $ | (11,094 | ) | $ | (9,345 | ) | ||||
Basic and diluted weighted average shares used in computing basic and diluted net loss per common share | 1,500,409 | 489,624 | 1,168,277 | 402,074 | ||||||||||||
Basic and diluted net loss per common share | $ | (2.32 | ) | $ | (7.38 | ) | $ | (9.50 | ) | $ | (23.24 | ) |
Palisade Bio, Inc.
Condensed Consolidated Statements of Cash Flows (Unaudited)
(in thousands, except share and per share amounts)
Nine Months Ended September 30, | ||||||||
2024 | 2023 | |||||||
Net loss | $ | (11,094 | ) | $ | (9,329 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation | 3 | 4 | ||||||
Non-cash operating lease expense | 85 | 76 | ||||||
Recurring fair value measurements of liabilities | (159 | ) | 153 | |||||
Issuance of common stock to vendors | 124 | — | ||||||
Loss on disposal of property and equipment | 4 | — | ||||||
Stock-based compensation and related charges | 575 | 439 | ||||||
Other | — | (108 | ) | |||||
Changes in operating assets and liabilities: | ||||||||
Prepaid and other current assets and other noncurrent assets | 542 | 596 | ||||||
Accounts payable and accrued liabilities | 526 | (184 | ) | |||||
Accrued compensation and benefits | (329 | ) | 43 | |||||
Operating lease liabilities | (89 | ) | (77 | ) | ||||
Net cash used in operating activities | (9,812 | ) | (8,387 | ) | ||||
Cash flows from investing activities: | ||||||||
Purchases of property and equipment | — | (4 | ) | |||||
Net cash used in investing activities | — | (4 | ) | |||||
Cash flows from financing activities: | ||||||||
Payments on insurance financing debt | (270 | ) | (290 | ) | ||||
Proceeds from issuance of common stock and warrants | 4,000 | 9,419 | ||||||
Proceeds from the exercise of warrants | 2,503 | 2,758 | ||||||
Payment of warrant inducement issuance costs | (343 | ) | — | |||||
Payment of equity issuance costs | (456 | ) | (567 | ) | ||||
Proceeds from issuance of common stock under Employee Stock Purchase Plan | 11 | — | ||||||
Shares withheld for payment of employee withholding tax liability | (25 | ) | — | |||||
Net cash provided by financing activities | 5,420 | 11,320 | ||||||
Net (decrease) increase in cash, cash equivalents and restricted cash | (4,392 | ) | 2,929 | |||||
Cash, cash equivalents and restricted cash, beginning of year | 12,458 | 12,409 | ||||||
Cash, cash equivalents and restricted cash, end of period | $ | 8,066 | $ | 15,338 | ||||
Reconciliation of cash, cash equivalents and restricted cash to the balance sheets: | ||||||||
Cash and cash equivalents | $ | 8,040 | $ | 15,312 | ||||
Restricted cash | 26 | 26 | ||||||
Total cash, cash equivalents and restricted cash | $ | 8,066 | $ | 15,338 |
FAQ
What is the current clinical trial status of PALI-2108?
What recent patent developments has Palisade Bio (PALI) achieved?
What manufacturing milestone did Palisade Bio (PALI) achieve for PALI-2108?